Monday, September 07, 2020 10:55:42 PM
Latane,
It sure is becoming increasingly obvious leronlimab is being purposely shunned. Approval should have happened over a hundred thousand lives ago, but small minds have prevailed.
I give NP credit for trying an "end run" (going outside of the US). Further, as a CEO he has an unusual background which makes him quite valuable to us, leronlimab, Cytodyn and humanity. He's a newcomer, an Iranian, a survivor, AND he's not in with the "in-crowd." This is extremely important - his efforts go to bringing leronlimab as a powerful medication to mankind. He's not busy trying to fit in with the power elite, instead he's on a crusade - a GOOD crusade.
So Options
*Approval in the US (only when they have no other choice)
*Approval overseas - Some countries are desperate enough and since the US (through the misguided efforts of our president) has lost significant "sway" and prestige, might make decisions disregarding pressure from the US to shun Cytodyn/leronlimab.
*Move the company to a foreign country (thinking outside the box - a radical move and one that would have to be carefully and quietly planned). If the goal is to make leronlimab available...
*Capitulate and be absorbed by BP. (Bad idea - leronlimab is too disruptive to their product lines - so it would be bought up to be put "on the shelf")
Suggestion - expedite LONG-HAULER/leronlimab study
Organized groups of long haulers (frustrated, angry, potential Bull-moose screamers and their supporters) already exist. It's a matter of getting them involved, focused, and utilize their communication networks to spread the word, influence, pressure, etc.
Also it changes the game. We're no longer competing for the cure/vaccine/treatment of Covid19 (wink). Instead we're competing with a smaller group that is seeking treatments for the immunological effects resulting from Covid19.
And...If the EINDs are any indication (along with the results after three days with the M-M study), we can be reasonably confident about the outcome. Should be easy to populate the study (folks will be clamoring to get in) and it won't be a long, drawn-out affair. Should know after day three, seven and fourteen if it is as effective as we suspect.
Slam dunk
It sure is becoming increasingly obvious leronlimab is being purposely shunned. Approval should have happened over a hundred thousand lives ago, but small minds have prevailed.
I give NP credit for trying an "end run" (going outside of the US). Further, as a CEO he has an unusual background which makes him quite valuable to us, leronlimab, Cytodyn and humanity. He's a newcomer, an Iranian, a survivor, AND he's not in with the "in-crowd." This is extremely important - his efforts go to bringing leronlimab as a powerful medication to mankind. He's not busy trying to fit in with the power elite, instead he's on a crusade - a GOOD crusade.
So Options
*Approval in the US (only when they have no other choice)
*Approval overseas - Some countries are desperate enough and since the US (through the misguided efforts of our president) has lost significant "sway" and prestige, might make decisions disregarding pressure from the US to shun Cytodyn/leronlimab.
*Move the company to a foreign country (thinking outside the box - a radical move and one that would have to be carefully and quietly planned). If the goal is to make leronlimab available...
*Capitulate and be absorbed by BP. (Bad idea - leronlimab is too disruptive to their product lines - so it would be bought up to be put "on the shelf")
Suggestion - expedite LONG-HAULER/leronlimab study
Organized groups of long haulers (frustrated, angry, potential Bull-moose screamers and their supporters) already exist. It's a matter of getting them involved, focused, and utilize their communication networks to spread the word, influence, pressure, etc.
Also it changes the game. We're no longer competing for the cure/vaccine/treatment of Covid19 (wink). Instead we're competing with a smaller group that is seeking treatments for the immunological effects resulting from Covid19.
And...If the EINDs are any indication (along with the results after three days with the M-M study), we can be reasonably confident about the outcome. Should be easy to populate the study (folks will be clamoring to get in) and it won't be a long, drawn-out affair. Should know after day three, seven and fourteen if it is as effective as we suspect.
Slam dunk
Recent CYDY News
- CytoDyn to Host Investor Webcast • GlobeNewswire Inc. • 04/23/2026 12:30:00 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 04/22/2026 09:21:50 PM
- CytoDyn Presents New Leronlimab Data in Metastatic Colorectal Cancer at AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/22/2026 12:30:00 PM
- CytoDyn Completes Enrollment in Phase 2 Metastatic Colorectal Cancer Study • GlobeNewswire Inc. • 04/21/2026 08:10:00 PM
- CytoDyn Presents New Leronlimab Data in Metastatic Triple-Negative Breast Cancer at AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/20/2026 12:30:00 PM
- CytoDyn to Present at the AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/14/2026 12:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 04/08/2026 09:15:18 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 04/08/2026 12:30:28 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/25/2026 09:16:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:24:23 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:23:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:22:42 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:21:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:20:57 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:20:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/24/2026 09:15:24 PM
- CytoDyn Presents at AACR Special Conference in Cancer Research: Brain Cancer • GlobeNewswire Inc. • 03/24/2026 12:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/09/2026 09:15:18 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/05/2026 01:35:02 PM
- CytoDyn Closes $17.5 Million Financing to Fund Continued Development of Leronlimab • GlobeNewswire Inc. • 03/05/2026 01:30:00 PM
- CytoDyn Presents Novel CCR5 Inhibition Mechanisms and Long-Term Survival Signals for Leronlimab in Metastatic Breast Cancer at AACR Immuno-Oncology Conference • GlobeNewswire Inc. • 02/20/2026 01:30:00 PM
- CytoDyn Announces Funding and Initiation of Expanded Access Program for Patients with Triple-negative Breast Cancer • GlobeNewswire Inc. • 01/27/2026 01:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 01/09/2026 10:15:22 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 01/09/2026 01:30:45 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 12/22/2025 10:15:23 PM
